Multiple myeloma trials in Türkiye

In Türkiye 12 Also abroad 705

10 of 12 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Where
Ankara, Istanbul, Izmir, Mamak
Age
18 years and over
People
915 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00
Phase 3Active, not recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Ankara, Antalya, Denizli, Istanbul, Izmir, Samsun
Age
18 years and over
People
1,590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
Phase 3Taking people
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Where
Ankara, Antalya, Istanbul, Izmir, Samsun
Age
18 years and over
People
1,000 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07665450
Phase 3Active, not recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Ankara, Istanbul, Izmir, Kayseri, Samsun
Age
18 years and over
People
810 worldwide
Run by
Celgene
See details and how to joinNCT05519085
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Ankara
Age
18 years and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
Phase 3Taking people
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Ankara, Antalya, Istanbul, Izmir, Mersin, Samsun
Age
18 years and over
People
700 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07518186
Phase 3Terminated
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Adana, Ankara, Antalya, Gaziantep, Istanbul, Izmir, Kayseri, Kocaeli, Malatya
Age
18 years and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
Phase 1/2Taking people
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Where
Istanbul, Kayseri
Age
18 years and over
People
123 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00
Phase 3Taking people
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Where
Adana, Ankara, Kocaeli, Samsun, Sisli - Istanbul
Age
18 years and over
People
520 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00
Phase 3Taking people
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Where
Ankara, Izmir
Age
18 years and over
People
1,000 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00